Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody
T. Arai (Sakai, Japan), T. Kasai (Sakai, Japan), A. Matsumuro (Sakai, Japan), C. Sugimoto (Sakai, Japan), M. Hirose (Sakai, Japan), N. Takeuchi (Sakai, Japan), K. Katayama (Sakai, Japan), M. Akira (Sakai, Japan), M. Kitaichi (Tanabe, Japan), Y. Inoue (Sakai, Japan)
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Arai (Sakai, Japan), T. Kasai (Sakai, Japan), A. Matsumuro (Sakai, Japan), C. Sugimoto (Sakai, Japan), M. Hirose (Sakai, Japan), N. Takeuchi (Sakai, Japan), K. Katayama (Sakai, Japan), M. Akira (Sakai, Japan), M. Kitaichi (Tanabe, Japan), Y. Inoue (Sakai, Japan). Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody. 3016
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018
Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012
Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010
Cross-sectional and longitudinal measurement of autoantibody levels against GM-CSF is useful for predicting clinical courses of in autoimmune pulmonary alveolar proteinosis. Source: International Congress 2017 – Rare diseases Year: 2017
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
Clinical and paraclinical manifestations of pulmonary alveolar proteinosis in children Source: Eur Respir J 2007; 30: Suppl. 51, 402s Year: 2007
Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002
Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency Source: Eur Respir J 2016; 48: 1510-1514 Year: 2016
Anti-elastin autoantibodies are not present in combined pulmonary fibrosis and emphysema Source: Eur Respir J 2009; 33: 219-221 Year: 2009
Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009
Lymphocytes populations in bloods and lungs in patients with auto-immune pulmonary alveolar proteinosis Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011
Cytokine regulation in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis: clinicomorphological study Source: Eur Respir J 2001; 18: Suppl. 33, 107s Year: 2001
MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013
Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004
Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016
Occupational and environmental impact on the clinical course of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012